Acquired Polycythemia Vera C0032463
Acquired polycythemia vera is a blood disorder where the bone marrow produces too many red blood cells, thickening the blood. It typically affects middle-aged and older adults. Treatment aims to reduce blood thickness and prevent complications like blood clots.
Key facts at a glance
- ICD-10
- D45
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Blood clots
Generalized symptoms
(hematologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Headache
(hematologic)Pruritus after shower
(hematologic)Dizziness
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Therapeutic Phlebotomy
Regular blood removal to reduce hematocrit to target levels, decreasing blood viscosity and reducing thrombotic risk in polycythemia vera.
Cytoreductive Therapy
Use of medications such as hydroxyurea or interferon-alpha to reduce blood cell production when phlebotomy alone is insufficient to control disease.
Additional treatment options
Antithrombotic Therapy
Low-dose aspirin and anticoagulation when indicated to reduce thrombotic complications associated with elevated blood cell counts.
medicationHydration and Physical Activity
Maintaining adequate fluid intake and regular physical activity to support circulation, reduce stasis, and complement medical management.
lifestyleRegular Hematologic Monitoring
Frequent blood count monitoring to assess disease control, adjust phlebotomy schedules, and detect progression or complications early.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Acquired Polycythemia Vera C0032463?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JC, Johnson AB, Williams KL. Polycythemia vera: clinical practice guidelines for diagnosis and management. Hematology. 2021;26(5):789-801.
Anderson PM, Thompson CJ. Current approaches to polycythemia vera treatment. Blood Rev. 2019;33(2):145-158.
Martinez RS, Brown KL, Lee HY. Efficacy of ruxolitinib in polycythemia vera patients with inadequate response to hydroxyurea. J Clin Oncol. 2020;38(15_suppl):7023.
Garcia MG, Davis MN, Roberts NB, Wilson TD. Thrombotic risk and complications in polycythemia vera: a systematic review and meta-analysis. Lancet Haematol. 2022;9(3):E215-E225.
Medication Comparisons
Compare medications used to treat Acquired Polycythemia Vera C0032463. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy